Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC

J Thorac Oncol. 2018 Jun;13(6):e89-e91. doi: 10.1016/j.jtho.2018.03.013. Epub 2018 Mar 27.

Affiliations

¹ Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
² Department of Medicine and Surgery, University of Parma, Parma, Italy.
³ Pathology Unit, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy.
⁴ Department of Medicine and Surgery, University of Parma, Parma, Italy. Electronic address: roberta.alfieri@unipr.it.

PMID: 29596911
DOI: 10.1016/j.jtho.2018.03.013

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Acrylamides / therapeutic use*
Aged
Aniline Compounds / therapeutic use*
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Drug Resistance, Neoplasm
ErbB Receptors / genetics
Female
Gene Amplification
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Mutation
Proto-Oncogene Proteins B-raf / genetics*
Proto-Oncogene Proteins c-met / genetics*

Substances

Acrylamides
Aniline Compounds
Antineoplastic Agents
osimertinib
EGFR protein, human
ErbB Receptors
MET protein, human
Proto-Oncogene Proteins c-met
BRAF protein, human
Proto-Oncogene Proteins B-raf